CGT Catapult: Funding, Investors & Team (Oct 2026)
The Cell and Gene Therapy Catapult is a centre of excellence in innovation, with the core purpose of building a world-leading cell and gene therapy sector in the UK as a key part of a global industry. Supported by Innovate UK, their mission is to drive the growth of the industry by helping cell and gene therapy organisations across the world translate early stage research into commercially viable and investable therapies. They are based on the 12th floor of Guy’s Hospital in central London, with over 120 cell and gene therapy experts, state-of-the art development and viral vector laboratories. They are also building a £55m large-scale GMP manufacturing centre to help bring cell and gene therapies to market in the UK and internationally.
CGT Catapult has raised $1.5M across 1 funding round on record, the most recent an undisclosed round of $1.5M announced in Jun 2023.
That round is below the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
CGT Catapult Company Profile and Key Stats
Latest funding round on record: Jun 2023.
CGT Catapult Funding Rounds
CGT Catapult Founders and Leadership Team
No contact details are on record for this team yet.
CGT Catapult Funding Compared to Other Biotechnology Startups
CGT Catapult's latest round of $1.5M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like CGT Catapult in Biotechnology and London
Companies Similar to CGT Catapult
Microbiotica develops treatments involving live bacteria found in the human microbiome, aiming to identify…
OMass Technologies is a drug discovery company exploiting novel mass spectrometry platforms to develop…
HydRegen, based in Oxford, UK, is a biotech firm that offers eco-friendly alternatives for the production of…
R1 Therapeutics is a clinical‑stage biopharmaceutical company focused on discovering and developing new drug…
The perfect package for any general surgical trainee or resident. Progress from beginner to advanced surgical…
Argonaute RNA company research projects build on existing intellectual property.
An innovative C elegans company that serves the biotech, nutrition, and other industries and fields of study…
ViaNautis, previously known as SomaServe, was established in 2018 as a separate entity from UCL under the…
Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of…
Biodexa Pharmaceuticals is an international specialty pharmaceutical company focused on oncology and other…
Concert Bio helps businesses create optimal microbial communities.
RQ Bio is a biotechnology company that develops long-acting monoclonal antibodies against seasonal influenza…
CGT Catapult Funding FAQs
What does CGT Catapult do?
The Cell and Gene Therapy Catapult is a centre of excellence in innovation, with the core purpose of building a world-leading cell and gene therapy sector in the UK as a key part of a global industry. Supported by Innovate UK, their mission is to drive the growth of the industry by helping cell and gene therapy organisations across the world translate early stage research into commercially viable and investable therapies. They are based on the 12th floor of Guy’s Hospital in central London, with over 120 cell and gene therapy experts, state-of-the art development and viral vector laboratories. They are also building a £55m large-scale GMP manufacturing centre to help bring cell and gene therapies to market in the UK and internationally.
How much funding has CGT Catapult raised?
CGT Catapult has raised $1.5M across 1 round on record. The most recent is an undisclosed round of $1.5M announced in Jun 2023.
When did CGT Catapult last raise funding?
CGT Catapult's most recent funding round on record is an undisclosed round of $1.5M, announced in Jun 2023.
Who founded CGT Catapult?
FundedIQ lists Mark Fuller (Founder) at CGT Catapult.
Where is CGT Catapult headquartered?
CGT Catapult is based in London, England, United Kingdom.
How many employees does CGT Catapult have?
CGT Catapult is in the 251-500 employee band.
How does CGT Catapult's funding compare to other Biotechnology startups?
CGT Catapult's latest round of $1.5M is below the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's CGT Catapult Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for CGT Catapult is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.